Center for Human Genetics

gbiomed.kuleuven.be

The Center for Human Genetics (Centrum Menselijke Erfelijkheid) is active in three domains: research, teaching and health services. The center focuses on hereditary diseases, cancer and neurological disorders. Its collaborators want to gain a better insight into these diseases, in order to assure patients a correct and timely diagnosis and a better treatment and support.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

news image

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More

DIAGNOSTICS

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

news image

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

news image

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More
news image

MEDICAL

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More
news image

DIAGNOSTICS

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More
news image

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More
news image

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More